Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.46 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.43 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9105817 | 0.88 | CYP2C9 (0.41) | KDRCCNCCDK8CYP2C9NAMPT | |
| SCHEMBL4465323 | 0.81 | ROCK2 (0.50) | CYP2C9NAMPT | |
| SCHEMBL13603542 | 0.81 | MAPK14 (0.58) | KDRHIPK4CCNCCDK8BRAF | |
| SCHEMBL4474322 | 0.80 | KDR (0.55) | KDRHIPK4CCNCCDK8BRAF | |
| SCHEMBL4485385 | 0.77 | KDR (0.52) | KDRHIPK4CCNCCDK8BRAF | |
| SCHEMBL171351 | 0.76 | KDR (0.47) | KDRHIPK4BRAFDDR2MAPK14 | |
| SCHEMBL4467015 | 0.75 | KDR (0.59) | KDRHIPK4CCNCCDK8BRAF | |
| SCHEMBL15573040 | 0.75 | KDR (0.56) | KDRHIPK4CCNCCDK8BRAF | |
| SCHEMBL9283605 | 0.73 | KDR (0.54) | KDRHIPK4BRAFDDR2MAPK14 | |
| SCHEMBL13603502 | 0.73 | MAPK14 (0.57) | KDRHIPK4CCNCCDK8BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598274-B2 | N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide; Raf kinases inhibitors | MERCK PATENT GMBH (DE) | 2009-10-06 | — | — | US | disclosed |
| US-20070149594-A1 | Pyrrole derivatives | MERCK PATENT GMBH (DE) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149594-A1 | Pyrrole derivatives | RAF1, BRAF, ARAF | KDR 2076/4885HIPK4 322/4885CCNC 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.